Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “C4 THERAPEUTICS, INC.”

24 pharma patents match "C4 THERAPEUTICS, INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 24
Index total 30,257
Page 1 / 1

Quick answer

This filtered view shows 24 pharmaceutical patents matching "C4 THERAPEUTICS, INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

24 results for “C4 THERAPEUTICS, INC.” · 30,257 patents in full index Clear search

  1. US 12421220

    Bicyclic-substituted glutarimide cereblon binders

    C4 THERAPEUTICS, INC. · Granted Sep 23, 2025 · Expires Sep 18, 2045

    granted
  2. US 12371442

    Isoindolinone and indazole compounds for the degradation of EGFR

    C4 THERAPEUTICS, INC. · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  3. US 12227504

    Spirocyclic compounds

    C4 THERAPEUTICS, INC. · Granted Feb 18, 2025 · Expires Feb 13, 2045

    granted
  4. US 12180225

    N/O-linked degrons and degronimers for protein degradation

    C4 THERAPEUTICS, INC. · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted
  5. US 12157735

    Compounds for targeted degradation of BRD9

    C4 THERAPEUTICS, INC. · Granted Dec 3, 2024 · Expires Nov 28, 2044

    granted
  6. US 12091397

    Dihydroquinolinones for medical treatment

    C4 THERAPEUTICS, INC. · Granted Sep 17, 2024 · Expires Sep 12, 2044

    granted
  7. US 12076405

    Heterocyclic degronimers for target protein degradation

    C4 THERAPEUTICS, INC. · Granted Sep 3, 2024 · Expires Aug 29, 2044

    granted
  8. US 12048747

    Substituted piperidine Degronimers for Target Protein degradation

    C4 THERAPEUTICS, INC. · Granted Jul 30, 2024 · Expires Jul 25, 2044

    granted
  9. US 12049464

    Compounds for targeted degradation of BRD9

    C4 THERAPEUTICS, INC. · Granted Jul 30, 2024 · Expires Jul 25, 2044

    granted
  10. US 12048748

    Spirocyclic degronimers for target protein degradation

    C4 THERAPEUTICS, INC. · Granted Jul 30, 2024 · Expires Jul 25, 2044

    granted
  11. US 11992531

    C3-carbon linked glutarimide degronimers for target protein degradation

    C4 THERAPEUTICS, INC. · Granted May 28, 2024 · Expires May 23, 2044

    granted
  12. US 11802131

    Glutarimides for medical treatment

    C4 THERAPEUTICS, INC. · Granted Oct 31, 2023 · Expires Oct 26, 2043

    granted
  13. US 11753397

    Cereblon binders for the degradation of ikaros

    C4 THERAPEUTICS, INC. · Granted Sep 12, 2023 · Expires Sep 7, 2043

    granted
  14. US 11691972

    Compounds for targeted degradation of BRD9

    C4 THERAPEUTICS, INC. · Granted Jul 4, 2023 · Expires Jun 29, 2043

    granted
  15. US 11673902

    Isoindolinone and indazole compounds for the degradation of EGFR

    C4 THERAPEUTICS, INC. · Granted Jun 13, 2023 · Expires Jun 8, 2043

    granted
  16. US 11623929

    Spirocyclic compounds

    C4 THERAPEUTICS, INC. · Granted Apr 11, 2023 · Expires Apr 6, 2043

    granted
  17. US 11584748

    Spirocyclic compounds

    C4 THERAPEUTICS, INC. · Granted Feb 21, 2023 · Expires Feb 16, 2043

    granted
  18. US 11459335

    N/O-linked Degrons and Degronimers for protein degradation

    C4 THERAPEUTICS, INC. · Granted Oct 4, 2022 · Expires Sep 29, 2042

    granted
  19. US 11401256

    Dihydroquinolinones for medical treatment

    C4 THERAPEUTICS, INC. · Granted Aug 2, 2022 · Expires Jul 28, 2042

    granted
  20. US 11185592

    Spirocyclic degronimers for target protein degradation

    C4 THERAPEUTICS, INC. · Granted Nov 30, 2021 · Expires Nov 25, 2041

    granted
  21. US 10905768

    Heterocyclic degronimers for target protein degradation

    C4 THERAPEUTICS, INC. · Granted Feb 2, 2021 · Expires Jan 28, 2041

    granted
  22. US 10849982

    C3-carbon linked glutarimide degronimers for target protein degradation

    C4 THERAPEUTICS, INC. · Granted Dec 1, 2020 · Expires Nov 26, 2040

    granted
  23. US 10660968

    Spirocyclic degronimers for target protein degradation

    C4 THERAPEUTICS, INC. · Granted May 26, 2020 · Expires May 21, 2040

    granted
  24. US 10646575

    Heterocyclic degronimers for target protein degradation

    C4 THERAPEUTICS, INC. · Granted May 12, 2020 · Expires May 7, 2040

    granted